Lactobreath: A Study to Diagnose Lactose Intolerance Using Breath Markers

Lactose Intolerance Clinical Trial

— Lactobreath  

Official title:

Lactobreath: A Pilot Study to Diagnose Lactose Intolerance Based on the Exhaled Breath Metabolome

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06177938
• Other study ID #: NEX_Lactobreath
• Status: Recruiting
• Phase: N/A
• Start date: January 2024
• Est. completion date: February 2025

Study information

• Verified date: January 2024
• Source: ETH Zurich
• Contact: Stamatios Giannoukos, PhD
• Phone: +41 44 632 61 12
• Email: stamatios.giannoukos[@]org.chem.ethz.ch
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Food intolerances affect many people and can cause discomfort and dietary challenges. One common cause is difficulty digesting certain carbohydrates called FODMAPs. Diagnosing food intolerance is often done by excluding and then slowly reintroducing these carbohydrates or using a hydrogen breath test, but these methods have limitations.

To address these issues, this project uses the breath we exhale to find markers for lactose intolerance as a model for food intolerance diagnosis. Our aim is to identify breath markers for lactose tolerance and intolerance and link them to metabolic traits, including those found in urine. We use a real-time breath analysis method and a special sensor to measure gases in the digestive system, and we also explore genetic factors using saliva samples.

This project aims to help clinicians better identify patients who should follow low FODMAP diets and provide non-invasive breath tests to predict how patients will respond to these diets. It will also advance the use of breath analysis for personalized nutrition, contributes to the broader field of food intolerance research, and has the potential to benefit millions of individuals worldwide.

Description:

Genetic and lactose tolerance screening For all eligible participants, a screening home test will be conducted. The home screening test kit will contain lactose powder and accompanying information in order for the subjects to conduct a lactose tolerance test (according to the LHBT protocol) at home. The test will be adapted from recent guidelines (https://www.esnm.eu/guidelines.html) that propose the use of 25g of lactose for lactose tolerance testing, including a questionnaire to quantitatively assess symptoms. The home screening test kit will also provide material to collect a saliva sample to determine genetic polymorphisms commonly modulating LP.

A total of 120 participants will be selected and distributed into three groups based on their LP genetic profiles and response to the ingestion of 25 g of lactose (lactose solution):

• 24 genetically LP subjects with no GI symptoms in response to the ingestion of lactose (group 1)

• 24 genetically lactase-non-persistent (LNP) subjects with no GI symptoms in response to the ingestion of lactose (group 2)

• 72 genetically LNP subjects with any GI symptoms in response to lactose ingestion (group 3).

Study procedures Baseline measures: For each subject, baseline measurement of microbiota and diet will be made within four weeks of the intervention day. The assessment of diet and the genomic characterization of the fecal microbiota will be performed in parallel with repeated measures

• Four 24 h dietary recalls will be completed using an adapted version of the myfood24 online platform on four consecutive days, during days -30 to -7, before the intervention day

• Three fecal samples will be collected by the participants at home, ideally on three consecutive days, on days +1, +2, and +3 relative to the first 24 h dietary recall.

Intervention day: The diet of all selected participants will be restricted for the three days before the carbohydrate challenge test day to ensure that all FODMAPs are avoided with a standardized diet provided to the participants for the three days before the test.

On the morning of the test day, the participants will be asked to collect their first test sample, the morning urine and consume 300 mL of water at home. Upon arrival in the test laboratory, the participants will deliver a further urine sample and baseline breath samples for the breath metabolome and hydrogen breath test. The urine samples will be used for metabolomics analysis and, in the case of female participants, for a pregnancy test. Participants with a positive pregnancy test will be excluded.

The participants will also fill out the questionnaire on LI (as used for the screening survey) to describe symptoms of LI before the test (baseline symptoms).

The 120 participants will be assigned to one of the two carbohydrate challenges using stratified randomization based on the three groups defined by the pre-screening tests. 100 participants will be assigned to the experimental intervention (lactose). The remaining 20 participants (4 participants from each groups 1 and 2 and 12 participants from group 3) will be assigned to the control intervention (glucose). The participants and investigators will be blinded during testing to the type of carbohydrate solution assigned.

For each participant, the carbohydrate solution will need to be consumed in a time-lapse of 5 min. Following the solution intake, participants will be asked to rinse their mouths with a standard quantity of water (500 mL) to avoid the detection of solution-relevant residual molecules in the oral cavity. The participants will swallow a commercially available gas-sensing capsule within the 5 minutes following the lactose or glucose solution intake to monitor intestinal gases and GI transit time.

Postprandial breath, exhaled breath condensate (EBC) and urine samples will then be collected at predefined times during the 6 h following consumption of the assigned test product. Breath sampling will be performed using a secondary electrospray ionization source coupled to a high-resolution mass spectrometry system (SESI-HR-MS) for direct and real-time detection of volatile organic compounds (VOC) and using an H2 breath sensor (e.g. QuinTron BreathTracker Digital Microlyzer) for detection of exhaled hydrogen. EBC samples will be collected using a spirometry filter connected to a glass cold trap cooled to -78°C. In addition, the participants will fill out the questionnaire for symptoms of LI to describe the symptoms during the 6 h postprandial assessment .

To normalize participants' hydration, particularly to facilitate the urine collection, the participants will be offered a standardized quantity of water based on their body weight to be consumed in regular portions during the post-ingestion period. No other foods or fluids will be permitted during the laboratory testing.

Intestinal excretion of the gas-sensing capsule will mark the end of the intervention. A follow-up visit to confirm the excretion of the gas-sensing capsule will conclude the study.

Additional subjects will be recruited should the number of participants completing the lactose and glucose tests fall below the targeted numbers.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: February 2025
• Est. primary completion date: February 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion criteria:

• Men and women

• Swiss and non-Swiss living in the Zurich area (if necessary, beyond Zürich in Switzerland),

• Ability/desire to provide informed consent and partake in the procedures of the study

• Aged 18-65 years at screening

• Agreement to refrain from all other treatments and products used for dairy intolerance (e.g., Lactaid® dietary supplements) during study involvement

• Willing to return for all study visits and complete all study-related procedures, including fasting before and during the intervention

• Able to understand and provide written informed consent in English and/or German.

Exclusion criteria:

• Allergic to milk

• Currently pregnant

• Currently lactating

• Cigarette smoking or other use of tobacco or nicotine-containing products within 3 months of screening

• Diagnosed with any of the following disorders known to be associated with abnormal GI motility: gastroparesis, amyloidosis, neuromuscular diseases (including Parkinson's disease), collagen vascular diseases, alcoholism, uremia, malnutrition, or untreated hypothyroidism

• History of surgery that alters normal GI tract function, including but not limited to:

GI bypass surgery, bariatric surgery, gastric banding, vagotomy, fundoplication, pyloroplasty (N.B. history of uncomplicated abdominal or GI surgeries such as removal of an appendix >12 months before screening will not be excluded)

• Suspected obscure GI bleeding

• Past or present: organ transplant, chronic pancreatitis, pancreatic insufficiency, symptomatic biliary disease, coeliac disease, diverticular disease, inflammatory bowel disease, strictures (suspected or known), fistulas, or any GI obstruction, gastroparesis, history of gastric bezoar or any other medical condition with symptoms that could confound collection of adverse events

• Diabetes mellitus

• Congestive heart failure

• Human immunodeficiency virus, hepatitis B, or hepatitis C

• Body mass index > 35 kg/m2

• Swallowing disorders or dysphagia to food or pills

• Presence of implantable or portable electro-mechanical medical devices (e.g. pacemakers)

• Recent bowel preparation for endoscopic or radiologic investigation within 4 weeks of screening (e.g., colonoscopy preparation)

• Chronic antacid and/or proton pump inhibitor use

• Recent use of systemic antibiotics, defined as use within 2 months prior to screening

• History of ethanol (alcohol) and/or drug abuse in the past 12 months

• Patients with severe irritable bowel syndrome (IBS) (i.e., IBS Symptom Severity Score >400)

• Dietary restrictions including vegan or vegetarian diet.

• Any other conditions/issues noted by the study staff and/or Principal Investigator that would impact participation and/or protocol compliance.

• Previous enrollment in another clinical trial within the last 3 months.

• Results of the screening test showing GI symptoms in response to lactose ingestion and genetic LP.

Related Conditions & MeSH terms

• Lactose Intolerance

Intervention

Dietary Supplement:
• Lactose solution/Glucose solution
Single ingestion of a lactose/glucose solution.

Locations

Country	Name	City	State
Switzerland	ETH Zurich	Zürich	Zurich

Sponsors (4)

Lead Sponsor	Collaborator
ETH Zurich	Agroscope Liebefeld-Posieux Research Station ALP, Swiss Allergy Centre, University of Zurich

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Diagnostic performance of the breath profile associated with lactose malabsorption (lactobreath profile)	Selected metabolites identified from exhaled breath after lactose intake that can collectively discriminate clinical traits associated with lactose malabsorption. Several parameters with be assessed: sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), the likelihood ratio of a positive test (LR+), the likelihood ratio of a negative test (LR-).	Breath samples will be collected at 9 time points following the ingestion of lactose (15 min, 30 min, 60 min, 90 min, 120 min, 180 min, 240 min, 300 min, and 360 min).
Secondary	Urine metabolome	Metabolites identified in urine samples using GC-qTOF (including lactose and its metabolites, galactose, galactitol, and galactonate).	Two pooled postprandial timepoints following lactose intake (0-3h and 3-6h)
Secondary	Metabolome of exhaled breath condensate (EBC) samples	Metabolites identified in EBC samples using standardized LC-MS methods (reversed-phase and HILIC) and GC-MS.	9 postprandial timepoints following lactose intake (15 min, 30 min, 60 min, 90 min, 120 min, 180 min, 240 min, 300 min, and 360 min)
Secondary	Hydrogen breath test	Dynamic assessment of the hydrogen in breath after dietary exposure using hydrogen breath sensor	9 postprandial timepoints following lactose intake (15 min, 30 min, 60 min, 90 min, 120 min, 180 min, 240 min, 300 min, and 360 min)
Secondary	Intestinal gases and GI transit assessment	Dynamic assessment of the environment of the intestine via a commercial gas-sensing capsule to evaluate intestinal gas concentrations (H2, O2, CO2, and CH4), pH and GI transit.	Semi-continuous (every 20 seconds) postprandial assessment following lactose intake until excretion of the capsule
Secondary	Clinical symptoms of lactose intolerance	Standardized questionnaire previously validated for the target population	5 postprandial timepoints following lactose intake (30 min, 60 min, 120 min, 180 min, and 360 min)